U.S. FDA panel reviews Baxter immune therapy's long-term safety

[riky]

U.S. FDA panel reviews Baxter immune therapy's long-term safety

By Toni Clarke Washington (Reuters) - Advisors to the U.S. Food and Drug Administration will meet on Thursday to discuss the relative risks and benefits of Baxter International Inc's experimental treatment for certain hereditary disorders of the immune system. The FDA on Wednesday posted its preliminary assessment of the data on its website. The FDA is not obligated to follow the recommendations of its advisors, but typically does so. These are genetic disorders in which certain cells of the immune system are missing, leading to a infections, recurrent pneumonia and abscesses of the organs.

Source: You are not allowed to view links. Register or Login